Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

Hologic, Inc. and Biotheranostics, Inc. unveiled new findings showcasing the impact of Breast Cancer Index® (BCI™) Test results on treatment decisions for patients with early-stage hormone receptor-positive (HR+) breast cancer. The data revealed a noteworthy shift in medical recommendations for extended endocrine therapy, with a surge of over 30% in suggestions for patients identified by the BCI Test as potentially benefiting from this approach. This emphasizes the test's valuable role in guiding personalized treatment plans for HR+ breast cancer patients.